NIAID Launches Phase 2 Trial for Novel TB Treatment Regimens
The National Institute of Allergy and Infectious Diseases is conducting Phase 2 trial (A5409/RAD-TB) to evaluate novel multidrug regimens for drug-susceptible pulmonary tuberculosis, comparing them to standard of care over 52 weeks.